Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueDepreciation ExpenseEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetReceivables - Other
Ratios

Akebia Therapeutics (AKBA) Short-Term Debt repayments (2019)

Akebia Therapeutics (AKBA) has disclosed Short-Term Debt repayments for 1 consecutive years, with $15.0 million as the latest value for Q1 2019.

  • On a quarterly basis, Short-Term Debt repayments changed N/A to $15.0 million in Q1 2019 year-over-year; TTM through Dec 2019 was $15.0 million, a N/A change, with the full-year FY2023 number at $32.0 million, down 3.03% from a year prior.
  • Short-Term Debt repayments was $15.0 million for Q1 2019 at Akebia Therapeutics.
  • In the past five years, Short-Term Debt repayments ranged from a high of $15.0 million in Q1 2019 to a low of $15.0 million in Q1 2019.